Development Highlights – During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongertinib Tablets), Putanning(R) (Meloxicam Injection (II)) and Anqixin(R) (Recombinant Human Coagulation Factor VIIa […]

Vancouver, British Columbia–(ACN Newswire via SeaPRwire.com – March 26, 2026) – Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the “Company” or “Casa”) is pleased to announce that it has received a large dataset of historic drill hole information […]

  Financial Highlights For the Year Ended 31 December 2025 (HK$ million) 2025 2024 Change Revenue  4,001.1 3,811.9 + 5.0% Gross Profit  1,385.1 1,312.1 + 5.6% Gross Profit margin 34.6% 34.4% + 0.2pp Profit attributable to owners of the Company  331.4 201.0 + 64.9% […]

HONG KONG, Mar 25, 2026 – (ACN Newswire via SeaPRwire.com) – On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13.02% year-on-year to RMB 31.63 […]